Authors: Michael E. Hurwitz, Daniel C. Cho, Arjun Vasant Balar, et. al. Abstract: 2623 Clinical Trial Registry Number: NCT02983045 Citation: J Clin Oncol 37, 2019 (suppl; abstr 2623) Background: PIVOT-02 is an ongoing phase 1/2 study of bempegaldesleukin (NKTR-214), a CD122-preferential IL-2 pathway agonist, plus nivolumab in patients with advanced solid...
Pro zobrazení tohoto obsahu je třeba být přihlášen.